Generic Central Nervous System Drugs Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What fueled the previous growth in the generic central nervous system drugs market?
The market size for generic central nervous system drugs has seen substantial growth recently. The trajectory shows a rise from $88.43 billion in 2024 to about $94.38 billion in 2025, with a compound annual growth rate (CAGR) of 6.7%. The driving forces behind the historically perceived growth include the growing number of surgeries, enhanced growth in rising markets, intensification in pharmaceutical research and development, the aging population, and an upsurge in healthcare spending.
What will be the generic central nervous system drugs market size in the future?
In the coming years, the market size for ginger ale is projected to experience robust growth, expanding to $3.74 billion in 2029 with a compound annual growth rate (CAGR) of 6.1%. Factors contributing to growth during this projection period include evolving consumer preferences, sustainable and ethical consumption practices, the boom in e-commerce, the demand for functional beverages, developments in mixology and culinary trends, as well as global expansion. The forecast period is also expected to witness trends such as craft and artisanal selections, reductions in sugar content, use of natural ingredients, functional beverages, premiumization, and experimentation with flavor infusions and blends.
Get your generic central nervous system drugs market report here!
What main drivers are fueling expansion in the generic central nervous system drugs market?
The upward trend in mental health disorders is speculated to boost the generic central nervous system (CNS) drug market’s expansion. In essence, a mental health disorder is a significant clinical disturbance of an individual’s cognitive processes, emotional management, or behaviour. Such disorders often correlate with distress or vital functional impairments. Generic CNS drugs are paramount in these disorders’ intervention because they offer cost-effective and readily available treatment alternatives. For example, data from the Health and Social Care Information Centre, a UK-based governmental agency that supplies content, data, and IT systems to professionals in the health and social care fields, showed an increase in the number of 17- to 19-year-olds suspected of having a mental disorder. The rate rose from 17.4% in 2021 to 25.7% in 2022. As a result, the rising occurrence of mental health disorders is propelling the growth of the generic CNS drug market.
What key areas define the segmentation of the global generic central nervous system drugs market?
The generic central nervous system drugs market covered in this report is segmented –
1) By Type: Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other Types
2) By Drug Classification: Branded Drugs, Generic Drugs
3) By Disease: Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer
4) By Route Of Administration: Oral, Intravenous, Intranasal Or Inhalation, Other Route Of Administrations
5) By Mode Of Purchase: Over-The-counter drugs, Prescription-Based Drugs
6) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Multiple Sclerosis (MS): Interferons, Glatiramer Acetate, Sphingosine-1 Phosphate Receptor Modulators, Monoclonal Antibodies
2) By Anti-Psychotic: Atypical Antipsychotics, Typical Antipsychotics
3) By Analgesics: Non-Opioid Analgesics, Opioid Analgesics, Combination Analgesics
4) By Anti-Parkinson Drugs: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics
5) By Anesthetics: General Anesthetics, Local Anesthetics
6) By Anti-Epileptics: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Mechanisms
7) By Anti-Depressants: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants
8) By Other Types: Cognitive Enhancers, Anxiolytics, Sleep Aids
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9315&type=smp
Who are the dominant players expanding their reach in the generic central nervous system drugs market?
Major companies operating in the generic central nervous system drugs market include Biogen Inc., Johnson & Johnson, Hoffmann-La Roche Ltd, Novartis AG, UCB, Sanofi, Pfizer Inc., Merck KGaA, Sumitomo Dainippon Pharma, AbbVie, Recipharm AB, Neuraxpharm, Sun Pharmaceutical limited, Ranbaxy Laboratories, Merz Pharma GmbH & Co. KGaAare, AstraZeneca, Apotex, Gilead Sciences, Bayer, GlaxoSmithKline, Amgen, Abbott Laboratories, Janssen Pharmaceutica, Teva Canada, Accord Healthcare Inc., Acerus Pharmaceuticals Corporation, Amgen, EMS Pharma, Hypermarcas, Eurofarma, Teuto Brasileiro, Biolab Farmaceutica, Cristalia, União Quimica, Boehringer Ingelheim, Eli Lilly and Company, Adcock Ingram
How are evolving market trends shaping generic central nervous system drugs Strategies?
Leading businesses in the generic central nervous system drugs market are concentrating their efforts on the creation of biosimilars for central nervous system (CNS) disorders. The introduction and endorsement of biosimilars for certain biologic medications used for CNS issues are on an uptrend, providing less expensive options than branded biologics. For example, Sandoz, a pharmaceutical company based in Switzerland, introduced natalizumab-sztn, the initial biosimilar for managing recurring forms of multiple sclerosis (MS) in October 2023. The conditions treated range from clinically isolated syndrome, relapsing-remitting MS, to active secondary progressive MS. MS is a chronic, progressive autoimmune disease that impacts the central nervous system. Most patients suffering from the disease experience periods of remission and relapse, detrimentally affecting their quality of life. The treatment is however, not recommended for patients diagnosed with progressive multifocal leukoencephalopathy (PML) or those who have previously experienced PML.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9315
Which regions are emerging as leaders in the generic central nervous system drugs market?
North America was the largest region in the generic central nervous system drugs market in 2024. The regions covered in the generic central nervous system drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Respiratory Diseases Drugs Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report
Metabolic Disorders Drugs Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report
Dermatology Drugs Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
